Effects of ω-3 polyunsaturated fatty acid combined with clomiphene on clinical efficacy，pregnancy and safety in patients with polycystic ovary syndrome
- VernacularTitle:ω-3多不饱和脂肪酸联合氯米芬对多囊卵巢综合征患者疗效、妊娠和安全性的影响
- Author:
Hailing HU
1
;
Qiongjiao ZHOU
1
;
Dan XIE
2
;
Yu CAI
3
Author Information
1. Dept. of Obstetrics and Gynecology，Hunan Prevention and Treatment Institute for Occupational Diseases，Changsha 410007，China
2. Dept. of Obstetrics and Gynecology，the Fourth Hospital of Changsha，Changsha 410006，China
3. Dept. of Gynecology，Hunan Hospital of Integrated Traditional Chinese and Western Medicine，Changsha 410006，China
- Publication Type:Journal Article
- Keywords:
polycystic ovary syndrome;
ω-3PUFA;
clomiphene;
pregnancy;
ovarian function;
oxidative stress
- From:
China Pharmacy
2026;37(9):1190-1194
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects of ω-3 polyunsaturated fatty acid （ω-3PUFA） combined with clomiphene on clinical efficacy， pregnancy and safety in patients with polycystic ovary syndrome （PCOS）. METHODS A retrospective analysis was performed on the clinical data of 112 PCOS patients who received treatment in Dept. of Obstetrics and Gynecology of Hunan Prevention and Treatment Institute for Occupational Diseases from January 2022 to December 2023. According to the different treatment regimens， the patients were divided into single-drug group （60 cases） and drug-combination group （52 cases）. Single-drug group was given clomiphene orally， and drug-combination group was given clomiphene+ω-3PUFA. Clinical efficacy， pregnancy status and the occurrence of adverse drug reaction （ADR） as well as ovarian function and oxidative stress indexes before and after treatment were compared between 2 groups. RESULTS The overall response rate （90.38% vs. 71.67%）， ovulation rate （84.62% vs. 61.67%）， and pregnancy rate （51.92% vs. 26.67%） were all markedly higher in drug combination group than single drug group （ P ＜0.05）. Before treatment， there was no statistical significance in ovarian function and oxidative stress indexes between 2 groups （ P ＞0.05）. Compared with before treatment， serum anti-Müllerian hormone levels， inhibin B concentr ations， and the number of cystic follicles in 2 groups were decreased significantly after 12 weeks of treatment （ P ＜0.05）. The endometrial thickness increased significantly （ P ＜0.05）， while the serum levels of malondialdehyde and advanced oxidation protein products decreased significantly （ P ＜0.05）； the activities of serum superoxide dismutase and glutathione peroxidase increased significantly （ P ＜0.05）； the improvement of drug combination group was significantly better than single drug group （ P ＜0.05）. The ovarian volumes in both groups were significantly smaller after treatment compared to before treatment （ P ＜0.05）， but there was no statistically significant difference between the two groups （ P ＞0.05）. There was no significant difference in the overall incidence of ADR between the two groups during the treatment （ P ＞0.05）. CONCLUSIONS The combination of ω-3PUFA and clomiphene has a definite therapeutic effect on PCOS， which can effectively reduce the body’s oxidative stress response， improve ovarian function， and increase ovulation and pregnancy rates.
